

# Top Growth Driver In The Opdivo Nivolumab Market 2025: Impact Of Rising Non-Small Cell Lung Cancer Incidence On Market

*Opdivo Nivolumab Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034*

LONDON, GREATER LONDON, UNITED KINGDOM, March 18, 2025

[/EINPresswire.com/](https://www.einpresswire.com/) -- Updated 2025  
Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!



The Business  
Research Company

The Business Research Company

How Has the [Opdivo Nivolumab Market](#) Evolved in Recent Years?

□The Opdivo nivolumab market has witnessed substantial growth, increasing from \$7,709.49 million in 2024 to an estimated \$8,335.54 million in 2025. □This reflects a Compound Annual Growth Rate (CAGR) of 8.1%.

“

The opdivo (nivolumab) market size is expected to see strong growth in the next few years. It will grow to \$11,281.56 million in 2029 at a compound annual growth rate (CAGR) of 7.9%.”

*The Business Research  
Company*

□Several key factors have contributed to this growth, including:

- oRising prevalence of cancer.
- oIncreased investments in research and development.
- oGrowth in healthcare infrastructure and spending.
- oHigher incidence of non-small cell lung cancer (NSCLC).
- oIncreased capital expenditure in healthcare for advanced medical equipment.

Get Your Free Sample of The Opdivo nivolumab Market Report:

<https://www.thebusinessresearchcompany.com/sample.aspx?id=19914&type=smp>

What Trajectory Will the Opdivo Nivolumab Market Take in the Future?

□The market is expected to continue its expansion, reaching \$11,281.56 million by 2029.  
□This growth will occur at a projected CAGR of 7.9%.  
□Several factors will drive this growth, including:

- oIncreased adoption of immunotherapy.
- oGreater awareness of immunotherapy benefits.
- oRising capital expenditure in healthcare.
- oExpanding applications of nivolumab across multiple indications.
- oA growing preference for immunotherapy-based treatments.
- Key trends shaping the forecast period include:
  - oOngoing product innovation.
  - oExpansion into new geographic markets.
  - oAdvancements in cancer research and clinical trials.
  - oA shift towards personalized medicine.

Order Your Report Now For A Swift Delivery:

<https://www.thebusinessresearchcompany.com/report/opdivo-nivolumab-global-market-report->

### What Major Factors Are Driving the Opdivo Nivolumab Market?

The increasing incidence of non-small cell lung cancer (NSCLC) is a significant driver of the Opdivo nivolumab market. NSCLC, which accounts for approximately 85% of all lung cancer cases, has been on the rise due to various factors such as smoking, environmental pollution, genetic mutations, and hereditary predisposition.

Opdivo functions by blocking the PD-1 receptor on immune cells, strengthening the immune system's ability to detect and destroy cancer cells. This mechanism enhances treatment effectiveness and improves patient outcomes.

### Who Are the Major Players in the Opdivo Nivolumab Market?

Key industry players shaping the Opdivo nivolumab market include Bristol-Myers Squibb and Ono Pharmaceutical. These companies have played a significant role in market expansion and innovation.

### What Are the Emerging Trends in the [Opdivo Nivolumab Global Market](#)?

One of the most notable trends in the Opdivo nivolumab market is the development of combination therapies. These therapies are designed to improve treatment effectiveness and broaden applications across multiple cancer types. By overcoming resistance mechanisms, combination treatments offer advanced cancer patients more extensive therapeutic options.

### How Is the [Opdivo Nivolumab Market Segmented](#)?

The Opdivo nivolumab market is segmented as follows:

#### 1.By Type:

- o40 mg/4 mL
- o100 mg/10 mL
- o240 mg/24 mL

#### 2.By Dosage:

- oInjection

- oSolution
- oOther Dosages
- 3.By Demographic:
  - oAdult
  - oPediatric
- 4.By Application:
  - oMelanoma
  - oNon-small Cell Lung Cancer (NSCLC)
  - oMalignant Pleural Mesothelioma
  - oClassical Hodgkin Lymphoma (CHL)
  - oSquamous Cell Carcinoma of the Head and Neck (SCCHN)
  - oRenal Cell Carcinoma (RCC)
  - oOther Applications
- 5.By End-User:
  - oHospitals
  - oClinics
  - oOther End Users

Which Geographical Regions Are Prominent in the Opdivo Nivolumab Market?

As of 2024, North America holds the largest market share in the Opdivo nivolumab market. However, Asia-Pacific is anticipated to be the fastest-growing region during the forecast period. Other regions covered in the market report include Western Europe, Eastern Europe, South America, the Middle East, and Africa.

Browse through more similar reports by The Business Research Company:

Protein Sequencing Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/protein-sequencing-global-market-report>

Protein Extracts From Single Cell Protein And Other Conventional Sources Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/protein-extracts-from-single-cell-protein-and-other-conventional-sources-global-market-report>

Cell Culture Protein Surface Coating Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/cell-culture-protein-surface-coating-global-market-report>

Learn More About The Business Research Company

The Business Research Company provides in-depth research and insights through a vast collection of 15,000+ reports spanning 27 industries and over 60 geographies. Backed by 1,500,000 datasets, extensive secondary research, and expert insights from industry leaders, we equip you with the knowledge needed to stay ahead in the market.

Our flagship offering, the Global Market Model, is a leading market intelligence platform that

delivers comprehensive and up-to-date forecasts to support strategic decision-making.

Contact Us:

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

Email: [info@tbrc.info](mailto:info@tbrc.info)

Follow Us On:

LinkedIn: <https://in.linkedin.com/company/the-business-research-company>

Twitter: [https://twitter.com/tbrc\\_info](https://twitter.com/tbrc_info)

YouTube: [https://www.youtube.com/channel/UC24\\_f10rV8cR5DxICpgmyFQ](https://www.youtube.com/channel/UC24_f10rV8cR5DxICpgmyFQ)

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

[info@tbrc.info](mailto:info@tbrc.info)

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/794874619>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.